I was right, see Page 25 below, BORR 57% vs 11% for Vervoy alone, and BMS needs help to 'stay in the game' for I/O combos...
Almost positive BMS will 'counter', I'd almost go 'all in' on that...
https://viralytics.com/wp-content/u...vestor-presentation-January-15-2017-FINAL.pdf
Vultures circling, and they're very hungry, look at the price action the last 12 mths, odd to say the least, and with money like this (below), I guess you can make things happen...
""From most to least, here’s the amount of cash drugmakers have to repatriate to the US as part of tax reform.
- Amgen – $US39 billion
- Gilead – $US32 billion
- Pfizer – $US22 billion
- Merck – $US20 billion
- J&J – $US14 billion
- AbbVie – $US10 billion
- Lilly – $US9 billion
- BMS – $US9 billion
- Celgene – $US9 billion
- Biogen – $US4 billion"
https://www.*.com.au/pharma-and-biotech-companies-with-capital-to-repatriate-2018-1?r=US&IR=T
ML
